Kyowa Kirin re-files Orexo's sublingual fentanyl in Japan
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has made an approval submission in Japan for KW-2246, a sublingual formulation of fentanyl citrate for the treatment of cancer pain licensed from the Swedish firm Orexo.